Johnson and Johnson's quarterly profit rises 3.3 percent

Written by Ruby Khatun Khatun Published On 2018-07-18T09:31:36+05:30 | Updated On 18 July 2018 9:31 AM IST

Johnson and Johnson reported a 3.3 percent rise in quarterly profit, as higher sales of cancer drugs Zytiga and Darzalex helped offset pressure on its blockbuster rheumatoid arthritis treatment Remicade.

The healthcare conglomerate's net earnings rose to $3.95 billion, or $1.45 per share, in the second quarter, from $3.83 billion, or $1.40 per share, a year earlier.

Sales rose to $20.83 billion from $18.84 billion.

(Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)

cancer drugsDarzalexJohnson and Johnsonprofitquarterly profitRemicaderheumatoid arthritisZytiga

Source : REUTERS

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Ruby Khatun Khatun